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Background :
The urea breath test (UBT) is regarded as a highly reliable, noninvasive tool for diagnosing Helicobacter pylori infection. We compared a recently developed low-dose 38 mg 13 C-urea capsule, which is able to eliminate oral urease effects and does not require positional changes during the test, with the conventionally used 100 mg 13 C-urea tablet method. Methods : Thirty-nine volunteers were tested under informed consent with both 13 C-UBT methods, Helifinder � and UBiT-IR300 � , with a minimum 2-week washout period. The pre-ingestion and 20-minute post-ingestion breath samples were analyzed with an isotope ratio mass spectrometer for Helifinder, and a nondispersive isotope-selective infrared spectrophotometer for UBiT samples.
Results : Helifinder method showed excellent agreement with UBiT among 19 positive and 20 negative cases (weighted kappa value, 1.0). Helifinder results (y) showed good agreement but with a proportional bias compared to UBiT results (x) by Passing and Bablok method (y=0.551x-0.255, r=0.74, P<0.0001).
Conclusions : Since the low-dose 38 mg 13 C-urea capsule (Helifinder) test, which is more convenient and economic, showed comparable results with the conventional UBiT method, it can be used as an alternative for the diagnosis of H. pylori infection. as epidemiological investigations [5] [6] [7] . The 13 C-UBT is based on the capacity of the H. pylori urease to hydrolyze urea to ammonia and carbon dioxide, which diffuses into the blood, and is excreted by the lungs. Thus, by labeling urea with 13 C, the presence of H. pylori in the stomach can be identified by detecting 13 C in the expired breath sample with measuring equipments such as an isotope ratio mass spectrometer (IRMS), a nondispersive isotopeselective infrared spectroscopy (NDIRS), or a laser-assisted ratio analysis (LARA). During recent years, the 13 C-UBT has made several modifications to provide a more innocuous, simplified, and applicable procedure to be used in the clinical setting. Although the 14 C-labelled urea can also be utilized for UBTs, this radioactive isotope brought up problems dealing with hospital department licensing for storage and disposal of radioactive substrates and, more importantly, radiation exposure for the patients [8, 9] . In contrast, the non-radioactive stable isotope 13 C is innocuous enough that the 13 C-UBT can be repeated as often as required in the same patient and can also be safely performed in children and women of child-bearing age.
Moreover, lowering the dose of 13 C is an advantageous attempt to provide a more risk-free UBT technique for H. pylori detection.
In this study, we compared a recently developed lowdose urea capsule that uses an IRMS system with the conventional 13 C-UBT for detection of H. pylori infection. The currently used UBiT method was employed as the reference standard since a growing number of studies with favorable results for this tablet-based 13 C-UBT implementing the NDIRS have been reported [10, 11] .
MATERIALS AND METHODS

Study population
Apparently healthy volunteers were recruited for the comparative 13 C-UBT study. On receiving approval from the Institutional Review Board (IRB), the study was con- 
Study phases
The low-dose 38 mg 13 C-urea capsule (Helifinder   �   ; InBioNet Pharmaceutical, Ichon, Korea) method was tested followed by a 2-week washout period before performing the 13 C-UBT using the 100 mg 13 C-urea tablets (UBiT   �   ; Otsuka Pharmaceutical, Tokyo, Japan). Both urea breath tests required a minimum of 4-hour overnight fasting prior to testing for all participants. 13 C was measured as the 13 CO2: 12 CO2 isotope ratio and expressed as delta over base-
The first phase of the study protocol was done by urea breath testing using the Helifinder capsules, which contained polyethylene glycol (PEG) 4000 to enhance the dissolution of urea. The baseline breath sample was collected in a white-labeled test tube through a straw, and 20 minutes after ingestion of the capsule with 50 mL of water, a second breath sample was collected in a bluelabeled test tube. The 13 CO2 levels in the before and after 13 C administration breath samples were analyzed using an isotope ratio mass spectrometer (IRMS, Medichems, Seoul, Korea). If the change ( 13 C: ) from the baseline (pre-ingestion) level at 20 minutes after ingestion was 2.0 or higher, the patient was determined as H. pyloriinfected, and non-infected if lower than 2.0 [12] .
The second phase required collection of a pre-administration breath sample in a special breath-sampling bag, before ingestion of one film-coated 13 C-urea tablet (UBiT) with 100 mL of water. Subsequently, participants remained in the left lateral decubitus position for 5 minutes upon which they sat up to a sitting position for further 15 minutes, before the 20-minute breath sample was taken. The 13 CO2 levels in these breath samples were analyzed by a nondispersive isotope-selective infrared spectrophotometer (NDIRS; UBiT-IR300; Otsuka Electronics, Osaka Japan) and likewise, H. pylori infection was determined using 13 C( ), the calculated difference between pre-administration and 20-minute breath sample. A H. pylori-positive result was given when the 13 C was more than 2.5 , and H. pylori-negative when the 13 C was less than 2.5 . We repeated the Helifinder test following the UBiT test for 8 available cases after an additional 2-week washout period. A rapid urease test (CKD Bio Hp, Seoul, Korea) was performed during the endoscopic gastrointestinal biopsy in some of the patients. 
Statistical analysis
RESULTS
Of the 39 apparently healthy volunteers between the age of 22 to 60 (mean±standard deviation, 37.6±9.75) with a male to female ratio of 12:27 (Table 1) , 19 were positive by both Helifinder and UBiT methods with excellent agreement between the two methods (weighted kappa value, 1.0, Table 2 ). The DOB value of Helifinder (y, )
showed good agreement but with a proportional bias compared to UBiT (x, ) by the Passing and Bablok method (y=0.551x-0.255, r= 0.74, P<0.0001, Fig. 1 ). Initially, a discrepant case with Helifinder-positive (13.97 ) and In addition, the one inconsistent case in our study group may suggest that UBiT may show false negative results, which may be due to inappropriate positional changing or inadequately exhaled breath samples.
We could conclude that in comparison to the conventional UBiT (100 mg 13 C-urea tablet) method, the new low-dose capsule was appealing to a wide range of patients including children and the elderly as well as being comparable in quality and cost. Therefore, the Helifinder � 13 C-UBT is considered to be a convenient and valid alternative to the conventional UBiT for the diagnosis of H. pylori infection. 
